DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A-Hydrocort (Hydrocortisone Sodium Succinate) - Summary

 
 



A-HYDROCORT SUMMARY

A-HYDROCORT®

A-Hydrocort sterile powder contains hydrocortisone sodium succinate as the active ingredient. Hydrocortisone sodium succinate, is a white, or nearly white, odorless, hygroscopic, amorphous solid. It is very soluble in water and in alcohol, very slightly soluble in acetone and insoluble in chloroform.

When oral therapy is not feasible, and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, A-Hydrocort sterile powder is indicated for intravenous or intramuscular use in the following conditions:

Endocrine Disorders


Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance)


Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used)


Preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful


Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected


Congenital adrenal hyperplasia


Hypercalcemia associated with cancer


Nonsuppurative thyroiditis


Rheumatic Disorders


As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:


Post-traumatic osteoarthritis


Synovitis of osteoarthritis


Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)


Acute and subacute bursitis


Epicondylitis


Acute nonspecific tenosynovitis


Acute gouty arthritis


Psoriatic arthritis


Ankylosing spondylitis

Collagen Diseases


During an exacerbation or as maintenance therapy in selected cases of:


Systemic lupus erythematosus


Systemic dermatomyositis (polymyositis)


Acute rheumatic carditis


Dermatologic Diseases


Pemphigus


Severe erythema multiforme (Stevens-Johnson syndrome)


Exfoliative dermatitis


Bullous dermatitis herpetiformis


Severe seborrheic dermatitis


Severe psoriasis


Mycosis fungoides


Allergic States


Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:


Bronchial asthma


Contact dermatitis


Atopic dermatitis


Serum sickness


Seasonal or perennial allergic rhinitis


Drug hypersensitivity reactions


Urticarial transfusion reactions


Acute noninfectious laryngeal edema (epinephrine is the drug of first choice)


Ophthalmic Diseases


Severe acute and chronic allergic and inflammatory processes involving the eye, such as:


Herpes zoster ophthalmicus


Iritis, iridocyclitis


Chorioretinitis


Diffuse posterior uveitis and choroiditis


Optic neuritis


Sympathetic ophthalmia


Anterior segment inflammation


Allergic conjunctivitis


Allergic corneal marginal ulcers


Keratitis


Gastrointestinal Diseases


To tide the patient over a critical period of the disease in:


Ulcerative colitis (systemic therapy)


Regional enteritis (systemic therapy)


Respiratory Diseases


Symptomatic sarcoidosis


Berylliosis


Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy


Loeffler’s syndrome not manageable by other means


Aspiration pneumonitis

Hematologic Disorders


Acquired (autoimmune) hemolytic anemia


Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated)


Secondary thrombocytopenia in adults


Erythroblastopenia (RBC anemia)


Congenital (erythroid) hypoplastic anemia


Neoplastic Diseases


For palliative management of:


Leukemias and lymphomas in adults


Acute leukemia of childhood


Edematous States


To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus


Nervous System


Acute exacerbations of multiple sclerosis


Miscellaneous


Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy


Trichinosis with neurologic or myocardial involvement



See all A-Hydrocort indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to A-Hydrocort (Hydrocortisone)

Effects of standard glucocorticoid replacement therapies on subjective well-being: a randomized, double-blind, crossover study in patients with secondary adrenal insufficiency. [2012]
double-blind study design... CONCLUSIONS: Although the observed improvements in psychological parameters were

Effects of midazolam and nitrous oxide on endocrine and metabolic measurements in children. [2012]
children... CONCLUSIONS: When sedation is insufficient during i.v. access, and blood sampling

Randomized, double-blind, split-side comparison study of moisturizer containing licochalcone vs. 1% hydrocortisone in the treatment of infantile seborrhoeic dermatitis. [2012]
hydrocortisone for the treatment of ISD... CONCLUSION: Moisturizer containing 0.025% licochalcone had higher cure rate

Designing and conducting a randomized trial for pandemic critical illness: the 2009 H1N1 influenza pandemic. [2011.11.26]
PURPOSE: To analyze the hurdles in implementing a randomized trial of corticosteroids for severe 2009 H1N1 influenza infections... CONCLUSION: This report highlights the main hurdles in implementing a randomized trial for a pandemic critical illness and proposes solutions for future trials.

Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. [2011.11.17]
BACKGROUND: Tacrolimus is a topical calcineurin inhibitor with immunomodulatory, anti-inflammatory, and fungicidal properties that may be beneficial in the treatment of facial seborrheic dermatitis. OBJECTIVES: We sought to compare the efficacy and safety of tacrolimus with standard corticosteroid treatment in adults with facial seborrheic dermatitis in a phase II, single-blind, randomized controlled trial... CONCLUSION: Tacrolimus 0.1% ointment required significantly fewer applications compared with hydrocortisone 1% ointment to achieve a comparable clinical response in adults with facial seborrheic dermatitis. Tacrolimus was generally well tolerated. Copyright (c) 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

more studies >>

Clinical Trials Related to A-Hydrocort (Hydrocortisone)

Contribution of Salivary Cortisol in the Detection of Infra-clinic Cortisol Adenoma (ACIC) [Recruiting]

Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency [Not yet recruiting]
Patients with chronic adrenal insufficiency need to adapt their hydrocortisone replacement dose in conditions of physical or psychological stress to prevent life threatening adrenal crisis. In cases of more severe impairment or unsecure gastrointestinal absorption (e. g. gastroenteritis, severe infectious disease), parenteral administration of the hydrocortisone dose is crucial. The study is conducted to offer patients the possibility to perform hydrocortisone self administration in emergency situations in a way of administration which is easy to perform and accepted by the patient. Therefore, pharmacokinetics and safety of subcutaneous hydrocortisone administration will be studied and compared to intramuscular administration.

Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration [Recruiting]
The current study will test the causal relationship between elevated levels of cortisol and the serotonin transporter gene (5-HTTLPR) as these factors influence sensitivity to environmental threat. The investigators predict that carriers of the short allele of the serotonin transporter gene who have elevated cortisol levels will be most sensitive to threatening environments, whereas carriers of the long allele who do not have elevated cortisol (placebo subjects) will be least sensitive.

Trial of Hydrocortisone for Post-Traumatic Stress Disorder (PTSD) [Recruiting]
Developing novel and effective pharmacologic interventions for this post-traumatic stress disorder is important. The investigators propose to replicate findings of an earlier published pilot study using low dose hydrocortisone as a treatment for PTSD. In order to do so in a more meaningful way, the investigators will conduct a larger but similar randomized double-blind placebo-controlled, cross-over design treatment study examining the use of low dose hydrocortisone (or placebo) for 4 weeks in combat veterans suffering from PTSD.

The investigators hypothesize that, as described by Aerni et al. (2004), administration of daily hydrocortisone will lead to a reduction in PTSD symptom severity, but particularly for re-experiencing types (e. g., flashbacks, nightmares)of symptoms. The investigators also hope to examine potential predictors and moderators of treatment response based on subjects' clinical characteristics, as well as serum cortisol and ACTH levels.

Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT) [Recruiting]
The aim of this study is to investigate whether a physiologically low hydrocortisone (HC) dose is better for cognition as compared to a physiologically high HC dose. In addition, quality of life, metabolic profile and somatosensation will be described in relation to HC dose.

more trials >>


Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012